Exelixis Inc. has announced that its partner Ipsen has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use $(CHMP)$ regarding CABOMETYX® (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated neuroendocrine tumors. This recommendation is a crucial step towards obtaining final approval from the European Commission, expected in the coming months. The positive CHMP opinion follows the U.S. FDA's approval in March 2025, based on the phase 3 CABINET trial results. This development highlights the ongoing efforts to bring new treatment options to patients in Europe, addressing the need for effective therapies following disease progression.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。